Three-dimensional co-culture of human hepatocytes and mesenchymal stem cells: improved functionality in long-term bioreactor cultures

Journal of Tissue Engineering and Regenerative Medicine

Volumn 11, Issue 7, 2017, Pages 2034-2045

  Rebelo, Sofia P ^a,b   Costa, Rita ^a,b   Silva, Marta M ^a,b   Marcelino, Paulo ^c   Brito, Catarina ^a,b   Alves, Paula M ^a,b  

^a INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA   (Portugal)

^b INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^c NOVA MEDICAL SCHOOL   (Portugal)

Author keywords

BM MSCs; human hepatocytes; long term; spheroids; stirred tank bioreactor; three dimensional

Indexed keywords

BIOCONVERSION; CELL CULTURE; CELL ENGINEERING; COPYRIGHTS; FLOWCHARTING; GENE EXPRESSION; STEM CELLS; TANKS (CONTAINERS); TISSUE; TISSUE ENGINEERING; TOXICITY; UREA;

BONE MARROW MESENCHYMAL; BONE MARROW MESENCHYMAL STEM CELL; CO-CULTURES; HEPATOCYTES; HUMAN HEPATOCYTES; LONG-TERM; MARROW MESENCHYMAL STEM CELLS; SPHEROID; STIRRED TANK BIOREACTORS; TOXICITY TESTING;

BIOREACTORS;

CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; GLUCURONOSYLTRANSFERASE 1A1; LACTATE DEHYDROGENASE; MESSENGER RNA;

ARTICLE; BIOREACTOR; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL AGGREGATION; CELL CULTURE; CELL ISOLATION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CELLULAR DISTRIBUTION; COCULTURE; ENZYME ACTIVITY; ENZYME RELEASE; GENE; GENE EXPRESSION; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; LIVER CELL; MESENCHYMAL STEM CELL; PHENOTYPE; PRIORITY JOURNAL; STROMA CELL; UGT1A1 GENE; XENOBIOTIC METABOLISM; CELL CULTURE TECHNIQUE; CYTOLOGY; DEVICES; MESENCHYMAL STROMA CELL; METABOLISM; PROCEDURES;

BIOREACTORS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; COCULTURE TECHNIQUES; HEPATOCYTES; HUMANS; MESENCHYMAL STROMAL CELLS;

EID: 84949293968     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.2099     Document Type: Article

References (45)

1. Barakat O, Abbasi S, Rodriguez G et al. 2012; Use of decellularized porcine liver for engineering humanized liver organ. J Surg Res 173(1): e11–25.
2. Bruschi S. 2005; Methods and approaches to study metabolism and toxicity of acetaminophen. In Protocol Drug Metabolism and Transport Part of the series Methods in Pharmacology and Toxicology, Las L (ed.). Humana Press: NJ, USA; 197–232.
3. Corlu A, Ilyin G, Cariou S et al. 1997; The coculture: a system for studying the regulation of liver differentiation/proliferation activity and its control. ••••••••••••••••••••••••; 235–242.
4. Corlu A, Ilyin GP, Gérard N et al. 1994; Tissue distribution of liver regulating protein. Evidence for a cell recognition signal common to liver, pancreas, gonads, and hemopoietic tissues. Am J Pathol 145: 715–727.
5. De Bartolo L, Salerno S, Morelli S et al. 2006; Long-term maintenance of human hepatocytes in oxygen-permeable membrane bioreactor. Biomaterials 27: 4794–4803.
6. Dunn JCY, Tompkins RG, Yarmush ML 1992; Hepatocytes in collagen sandwich: evidence for transcriptional and translational regulation. J Cell Biol 116: 1043–1053.
7. Fitzpatrick E, Wu Y, Dhadda P et al. 2015; Coculture with mesenchymal stem cells results in improved viability and function of human hepatocytes. Cell Transpl 24: 73–83.
8. Ghannam S, Bouffi C, Djouad F et al. 2010; Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther 1: 2.
9. Godoy P, Hewitt NJ, Albrecht U et al. 2013; Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87(8): 1315–1530.
10. Gómez-Aristizábal A, Keating A, Davies JE 2009; Mesenchymal stromal cells as supportive cells for hepatocytes. Mol Ther 17: 1504–1508.
11. Gu J, Shi X, Zhang Y, et al. 2009; Heterotypic interactions in the preservation of morphology and functionality of porcine hepatocytes by bone marrow mesenchymal stem cells in vitro. J Cell Physiol 219: 100–108.
12. Gunes A, Dahl ML 2008; Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 9: 625–637.
13. Harvey A, Yen T-Y, Aizman I et al. 2013; Proteomic analysis of the extracellular matrix produced by mesenchymal stromal cells: implications for cell therapy mechanism. PLoS One 8(11): e79283.
14. Hewitt NJ, Lechón MJG, Houston JB et al. 2007; Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39: 159–234.
15. Holmgren G, Sjögren A-K, Barragan I et al. 2014; Long-term chronic toxicity testing using human pluripotent stem cell-derived hepatocytes. Drug Metab Dispos 42: 1401–1406.
16. Isoda K, Kojima M, Takeda M et al. 2004; Maintenance of hepatocyte functions by coculture with bone marrow stromal cells. J Biosci Bioeng 97: 343–346.
17. Jang YO, Kim YJ, Baik SK et al. 2014; Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. Liver Int 34: 33–41.
18. Jung J, Choi JH, Lee Y et al. 2013; Human placenta-derived mesenchymal stem cells promote hepatic regeneration in CCl4 -injured rat liver model via increased autophagic mechanism. Stem Cells 31: 1584–1596.
19. Kaibori M, Adachi Y, Shimo T et al. 2012; Stimulation of liver regeneration after hepatectomy in mice by injection of bone marrow mesenchymal stem cells via the portal vein. Transpl Proc 44: 1107–1109.
20. Khetani SR, Bhatia SN 2008; Microscale culture of human liver cells for drug development. Nat Biotechnol 26: 120–126.
21. Kim M-D, Kim S-S, Cha H-Y et al. 2014; Therapeutic effect of hepatocyte growth factor-secreting mesenchymal stem cells in a rat model of liver fibrosis. Exp Mol Med 46: e110.
22. Kostadinova R, Boess F, Applegate D et al. 2013; A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol Appl Pharmacol 268: 1–16.
23. LeCluyse EL, Witek RP, Andersen ME, et al. 2012; Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol 42: 501–548.
24. Lee K-D, Kuo TK-C, Whang-Peng J et al. 2004; In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology 40: 1275–1284.
25. Medine CN, Lucendo-Villarin B, Storck C et al. 2013; Developing high-fidelity hepatotoxicity models from pluripotent stem cells. Stem Cells Transl Med 2: 505–509.
26. Miranda JP, Leite SB, Muller-Vieira U et al. 2009; Towards an extended functional hepatocyte in vitro culture. Tissue Eng C Methods 15: 157–167.
27. Mizuguchi T, Palm K, Hui T et al. 2002; Effects of bone marrow stromal cells on the structural and functional polarity of primary rat hepatocytes. In Vitro Cell Dev Biol Anim 38: 62–65.
28. Nasir GA, Mohsin S, Khan M et al. 2013; Mesenchymal stem cells and interleukin-6 attenuate liver fibrosis in mice. J Transl Med 11: 78.
29. Rebelo SP, Costa R, Estrada M et al. 2015; HepaRG microencapsulated spheroids in DMSO-free culture: novel culturing approaches for enhanced xenobiotic and biosynthetic metabolism. Arch Toxicol 89(8): 1347–1358.
30. Salomone F, Barbagallo I, Puzzo L et al. 2013; Efficacy of adipose tissue-mesenchymal stem cell transplantation in rats with acetaminophen liver injury. Stem Cell Res 11: 1037–1044.
31. Schyschka L, Sánchez JJM, Wang Z et al. 2013; Hepatic 3D cultures but not 2D cultures preserve specific transporter activity for acetaminophen-induced hepatotoxicity. Arch Toxicol 87: 1581–1593.
32. Seglen PO 1976; Preparation of isolated rat liver cells. Methods Cell Biol 13: 29–83.
33. Slikker W Jr, Andersen ME, Bogdanffy MS et al. 2004; Dose-dependent transitions in mechanisms of toxicity. Toxicol Appl Pharmacol 201: 203–225.
34. Sun R, Jaruga B, Kulkarni S et al. 2005; IL-6 modulates hepatocyte proliferation via induction of HGF/p21 cip1: regulation by SOCS3. Biochem Biophys Res Commun 338: 1943–1949.
35. Szkolnicka D, Farnworth SL, Lucendo-Villarin B et al. 2014; Accurate prediction of drug-induced liver injury using stem cell-derived populations. Stem Cells Transl Med 3: 141–148.
36. Tostões RM, Leite SB, Miranda JP et al. 2011; Perfusion of 3D encapsulated hepatocytes – a synergistic effect enhancing long-term functionality in bioreactors. Biotechnol Bioeng 108: 41–49.
37. Tostões RM, Leite SB, Serra M et al. 2012; Human liver cell spheroids in extended perfusion bioreactor culture for repeated-dose drug testing. Hepatology 55: 1227–1236.
38. Treyer A, Müsch A 2013; Hepatocyte polarity. Comp Physiol 3: 243–287.
39. Tzanakakis ES, Hansen LK, Hu WS 2001; The role of actin filaments and microtubules in hepatocyte spheroid self-assembly. Cell Motil Cytoskel 48: 175–189.
40. Ullrich A, Stolz DB, Ellis EC et al. 2009; Long term cultures of primary human hepatocytes as an alternative to drug testing in animals. Altern Tierexperiment 26: 295–302.
41. Van Poll D, Parekkadan B, Cho CH et al. 2008; Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 47: 1634–1643.
42. Yang Y, Li J, Pan X et al. 2013; Co-culture with mesenchymal stem cells enhances metabolic functions of liver cells in bioartificial liver system. Biotechnol Bioeng 110: 958–968.
43. Yuan L, Kaplowitz N 2013; Mechanisms of drug-induced liver injury. Clin Liver Dis 17: 507–5148.
44. Zamek-Gliszczynski MJ, Xiong H, Patel NJ et al. 2003; Pharmacokinetics of 5 (and 6)-carboxy-2′,7′-dichlorofluorescein and its diacetate promoiety in the liver. J Pharmacol Exp Ther 304: 801–809.
45. Zhang S, Chen L, Liu T et al. 2012; Human umbilical cord matrix stem cells efficiently rescue acute liver failure through paracrine effects rather than hepatic differentiation. Tissue Eng A 18: 1352–1364.